All Stories

  1. Travel Medicine
  2. Metabolic gestational age assessment in low resource settings: a validation protocol
  3. Acceptability of a trial of vaginal progesterone for the prevention of preterm birth among HIV-infected women in Lusaka, Zambia: A mixed methods study
  4. Effects of Depot Medroxyprogesterone Acetate, Copper Intrauterine Devices, and Levonorgestrel Implants on Early HIV Disease Progression
  5. Development and external validation of machine learning algorithms for postnatal gestational age estimation using clinical data and metabolomic markers
  6. Is Group B Streptococcus Colonization Associated with Maternal Peripartum Infection in an Era of Routine Prophylaxis?
  7. Association Between Maternal Obesity and Group B Streptococcus Colonization in a National U.S. Cohort
  8. Machine Learning and Statistical Models to Predict Postpartum Hemorrhage
  9. Vaginal progesterone to prevent preterm delivery among HIV-infected pregnant women in Zambia: A feasibility study
  10. Adverse birth outcomes and their clinical phenotypes in an urban Zambian cohort
  11. Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination
  12. Postpartum endometritis and infection following incomplete or complete abortion: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data
  13. Cervical Cancer as a Global Concern
  14. Highly diverse anaerobe-predominant vaginal microbiota among HIV-infected pregnant women in Zambia
  15. The Zambian Preterm Birth Prevention Study (ZAPPS): Cohort characteristics at enrollment
  16. HIVserostatus, viral load, and midtrimester cervical length in a Zambian prenatal cohort
  17. Reducing the global burden of preterm births
  18. Improving preterm newborn identification in low-resource settings with machine learning
  19. Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial
  20. Risk Factors for Adverse Birth Outcomes in the PROMISE 1077BF/1077FF Trial
  21. Evolution of HIV-1 drug resistance after virological failure of first-line antiretroviral therapy in Lusaka Zambia
  22. Infant Human Immunodeficiency Virus–free Survival in the Era of Universal Antiretroviral Therapy for Pregnant and Breastfeeding Women
  23. Quantifying bias between reported last menstrual period and ultrasonography estimates of gestational age in Lusaka, Zambia
  24. Risk of stillbirth among Zambian women with a prior cesarean delivery
  25. Associations between health systems capacity and mother-to-child HIV prevention program outcomes in Zambia
  26. Maternal Decision-Making and Uptake of Health Services for the Prevention of Mother-to-Child HIV Transmission: A Secondary Analysis
  27. Improving preterm newborn identification in low-resource settings with machine learning
  28. The Zambian Preterm Birth Prevention Study (ZAPPS): Cohort characteristics at enrollment
  29. Timing of Initiation of Antiretroviral Therapy and Risk of Preterm Birth in Studies of HIV-infected Pregnant Women
  30. Involving both parents in HIV prevention during pregnancy and breastfeeding
  31. Women's decision-making and uptake of services to prevent mother-to-child HIV transmission in Zambia
  32. Antenatal corticosteroids for women at risk of imminent preterm birth in low-resource countries: the case for equipoise and the need for efficacy trials
  33. Vaginal progesterone to reduce preterm birth among HIV-infected pregnant women in Zambia: a feasibility study protocol
  34. Postnatal gestational age estimation using newborn screening blood spots: a proposed validation protocol
  35. In Reply
  36. Preconception ART and preterm birth: real effect or selection bias?
  37. Norovirus infections in young children in Lusaka Province, Zambia: clinical characteristics and molecular epidemiology
  38. Patient engagement in HIV care and treatment in Zambia, 2004-2014
  39. Maternal and Breastmilk Viral Load
  40. Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth
  41. Association of previous severe low birth weight with adverse perinatal outcomes in a subsequent pregnancy among HIV-prevalent urban African women
  42. Maternal and newborn outcomes at a tertiary care hospital in Lusaka, Zambia, 2008-2012
  43. Dosage of Sulfadoxine–Pyrimethamine and Risk of Low Birth Weight in a Cohort of Zambian Pregnant Women in a Low Malaria Prevalence Region
  44. Multiple Overimputation to Address Missing Data and Measurement Error
  45. Predictors and outcomes of low birth weight in Lusaka, Zambia
  46. A retrospective study of HIV, antiretroviral therapy, and pregnancy-associated hypertension among women in Lusaka, Zambia
  47. Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa
  48. Point-of-Care Virologic Testing to Improve Outcomes of HIV-Infected Children in Zambia
  49. 17-Hydroxyprogesterone caproate (17OHP-C) coverage among eligible women delivering at 2 North Carolina hospitals in 2012 and 2013: A retrospective cohort study
  50. Renewing focus on family planning service quality globally
  51. A Preliminary Assessment of Rotavirus Vaccine Effectiveness in Zambia
  52. Premature adult mortality in urban Zambia: a repeated population-based cross-sectional study
  53. A risk score to identify HIV-infected women most likely to become lost to follow-up in the postpartum period
  54. A Worldwide Epidemic: The Problem and Challenges of Preterm Birth in Low- and Middle-Income Countries
  55. Implementation and Operational Research
  56. The Effect of Cryotherapy on Human Papillomavirus Clearance Among HIV-Positive Women in Lusaka, Zambia
  57. Prevalence of hypertension and its treatment among adults presenting to primary health clinics in rural Zambia: analysis of an observational database
  58. Implementation and Operational Research
  59. Implementation and Operational Research
  60. The burden of cervical pre-cancer and cancer in HIV positive women in Zambia: a modeling study
  61. Population-Level Scale-Up of Cervical Cancer Prevention Services in a Low-Resource Setting: Development, Implementation, and Evaluation of the Cervical Cancer Prevention Program in Zambia
  62. A population-based cohort study of stillbirth among twins in Lusaka, Zambia
  63. Temporal Trends and Predictors of Modern Contraceptive Use in Lusaka, Zambia, 2004–2011
  64. Adherence to extended postpartum antiretrovirals is associated with decreased breast milk HIV-1 transmission
  65. Clinical Performance of Digital Cervicography and Cytology for Cervical Cancer Screening in HIV-Infected Women in Lusaka, Zambia
  66. Age at Antiretroviral Therapy Initiation Predicts Immune Recovery, Death, and Loss to Follow-Up Among HIV-Infected Adults in Urban Zambia
  67. A Mobile Phone-Based, Community Health Worker Program for Referral, Follow-Up, and Service Outreach in Rural Zambia: Outcomes and Overview
  68. Maximizing Benefits of New Strategies to Prevent Mother-to-Child HIV Transmission Without Harming Existing Services
  69. Depression, pregnancy, and HIV: the case to strengthen mental health services for pregnant and post-partum women in sub-Saharan Africa
  70. Trends in all-cause mortality during the scale-up of an antiretroviral therapy programme: a cross-sectional study in Lusaka, Zambia
  71. Universal combination antiretroviral regimens to prevent mother-to-child transmission of HIV in rural Zambia: a two-round cross-sectional study
  72. Effect of Baseline Renal Function on Tenofovir-Containing Antiretroviral Therapy Outcomes in Zambia
  73. Monitoring the performance of “screen-and-treat” cervical cancer prevention programs
  74. Estimating the cost-effectiveness of nutrition supplementation for malnourished, HIV-infected adults starting antiretroviral therapy in a resource-constrained setting
  75. Short Communication: Late Refills During the First Year of Antiretroviral Therapy Predict Mortality and Program Failure Among HIV-Infected Adults in Urban Zambia
  76. Utilization of Cervical Cancer Screening Services and Trends in Screening Positivity Rates in a ‘Screen-And-Treat’ Program Integrated with HIV/AIDS Care in Zambia
  77. Safe Pregnancy in the Worldʼs Poorest Countries Begins With Access and Ends With the Obstetricians
  78. Simultaneous Detection of Major Drug Resistance Mutations in the Protease and Reverse Transcriptase Genes for HIV-1 Subtype C by Use of a Multiplex Allele-Specific Assay
  79. Predictors of Patient Attrition According to Different Definitions for Loss to Follow-up
  80. Predictors and pregnancy outcomes associated with a newborn birth weight of 4000 g or more in Lusaka, Zambia
  81. Measuring Coverage in MNCH: Population HIV-Free Survival among Children under Two Years of Age in Four African Countries
  82. A common evaluation framework for the African Health Initiative
  83. Approaches to ensuring and improving quality in the context of health system strengthening: a cross-site analysis of the five African Health Initiative Partnership programs
  84. Field effectiveness of combination antiretroviral prophylaxis for the prevention of mother-to-child HIV transmission in rural Zambia
  85. Improving health information systems for decision making across five sub-Saharan African countries: Implementation strategies from the African Health Initiative
  86. Protocol-driven primary care and community linkages to improve population health in rural Zambia: the Better Health Outcomes through Mentoring and Assessment (BHOMA) project
  87. Monitoring of Antiretroviral Therapy and Mortality in HIV Programmes in Malawi, South Africa and Zambia: Mathematical Modelling Study
  88. Antiretroviral Drug Regimens to Prevent Mother-To-Child Transmission of HIV: A Review of Scientific, Program, and Policy Advances for Sub-Saharan Africa
  89. Nonvirologic Algorithms for Predicting HIV Infection Among HIV-exposed Infants Younger Than 12 Weeks of Age
  90. A Controlled Trial of Three Methods for Neonatal Circumcision in Lusaka, Zambia
  91. Taking ART to Scale: Determinants of the Cost and Cost-Effectiveness of Antiretroviral Therapy in 45 Clinical Sites in Zambia
  92. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries
  93. Six-Month Hemoglobin Concentration and Its Association With Subsequent Mortality Among Adults on Antiretroviral Therapy in Lusaka, Zambia
  94. Progress, Challenges, and New Opportunities for the Prevention of Mother-to-Child Transmission of HIV Under the US Presidentʼs Emergency Plan for AIDS Relief
  95. Coverage of the Prevention of Mother-to-Child Transmission Program in the Western Cape, South Africa Using Cord Blood Surveillance
  96. Effectiveness of generic and proprietary first-line anti-retroviral regimens in a primary health care setting in Lusaka, Zambia: a cohort study
  97. Comparative Outcomes of Tenofovir-Based and Zidovudine-Based Antiretroviral Therapy Regimens in Lusaka, Zambia
  98. Hyponatremia, Hypochloremia, and Hypoalbuminemia Predict an Increased Risk of Mortality During the First Year of Antiretroviral Therapy Among HIV-Infected Zambian and Kenyan Women
  99. Universal Definition of Loss to Follow-Up in HIV Treatment Programs: A Statistical Analysis of 111 Facilities in Africa, Asia, and Latin America
  100. Optimal Time on HAART for Prevention of Mother-to-Child Transmission of HIV
  101. Predictors of CD4 Eligibility for Antiretroviral Therapy Initiation Among HIV-Infected Pregnant Women in Lusaka, Zambia
  102. Nevirapine for the Prevention of Mother-to-Child Transmission of HIV: A Nation-Wide Coverage Survey in Côte dʼIvoire
  103. Advancing Cervical Cancer Prevention Initiatives in Resource-Constrained Settings: Insights from the Cervical Cancer Prevention Program in Zambia
  104. Determinants of Stillbirth in Zambia
  105. Causes of stillbirth, neonatal death and early childhood death in rural Zambia by verbal autopsy assessments
  106. Implementation of the Zambia Electronic Perinatal Record System for comprehensive prenatal and delivery care
  107. Modern Contraceptive and Dual Method Use among HIV-Infected Women in Lusaka, Zambia
  108. CD4+ cell count and risk for antiretroviral drug resistance among women using peripartum nevirapine for perinatal HIV prevention
  109. Transmission of HIV to infants whose mothers seroconvert postnatally
  110. Mobile phones to improve HIV treatment adherence
  111. Implementation of cervical cancer prevention services for HIV-infected women in Zambia: measuring program effectiveness
  112. Early immunologic response and subsequent survival among malnourished adults receiving antiretroviral therapy in Urban Zambia
  113. Coverage of Nevirapine-Based Services to Prevent Mother-to-Child HIV Transmission in 4 African Countries
  114. eC3-A Modern Telecommunications Matrix for Cervical Cancer Prevention in Zambia
  115. Serum Phosphate Predicts Early Mortality in Adults Starting Antiretroviral Therapy in Lusaka, Zambia: A Prospective Cohort Study
  116. Peripartum nevirapine exposure and subsequent clinical outcomes among HIV-infected women receiving antiretroviral therapy for at least 12 months
  117. Early Clinical and Programmatic Outcomes with Tenofovir-Based Antiretroviral Therapy in Zambia
  118. Methods and Baseline Results of a Repeated Cross-Sectional Survey to Assess the Public Health Impact of Antiretroviral Therapy in Lusaka, Zambia
  119. Are treatments for cervical precancerous lesions in less-developed countries safe enough to promote scaling-up of cervical screening programs? A systematic review
  120. Association Between Weight Gain and Clinical Outcomes Among Malnourished Adults Initiating Antiretroviral Therapy in Lusaka, Zambia
  121. A Cluster Randomized Trial of Routine HIV-1 Viral Load Monitoring in Zambia: Study Design, Implementation, and Baseline Cohort Characteristics
  122. An Empirical Approach to Defining Loss to Follow-up Among Patients Enrolled in Antiretroviral Treatment Programs
  123. Effectiveness of Non-nucleoside Reverse-Transcriptase Inhibitor-Based Antiretroviral Therapy in Women Previously Exposed to a Single Intrapartum Dose of Nevirapine: A Multi-country, Prospective Cohort Study
  124. Breastfeeding in HIV-Positive Women
  125. A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia
  126. Antiretroviral therapy in antenatal care to increase treatment initiation in HIV-infected pregnant women: a stepped-wedge evaluation
  127. Universal Antiretroviral Therapy for Pregnant and Breast‐Feeding HIV‐1–Infected Women: Towards the Elimination of Mother‐to‐Child Transmission of HIV‐1 in Resource‐Limited Settings
  128. Hormonal contraception and HIV disease progression: a multicountry cohort analysis of the MTCT-Plus Initiative
  129. Intrapartum Tenofovir and Emtricitabine Reduces Low-Concentration Drug Resistance Selected by Single-Dose Nevirapine for Perinatal HIV Prevention
  130. Lost but Not Forgotten—The Economics of Improving Patient Retention in AIDS Treatment Programs
  131. Predictors of Rapid HIV Testing Acceptance and Successful Nevirapine Administration in Zambian Labor Wards
  132. CD4+ Response and Subsequent Risk of Death Among Patients on Antiretroviral Therapy in Lusaka, Zambia
  133. Macronutrient Supplementation for Malnourished HIV‐Infected Adults: A Review of the Evidence in Resource‐Adequate and Resource‐Constrained Settings
  134. Causes of morbidity among HIV-infected children on antiretroviral therapy in primary care facilities in Lusaka, Zambia
  135. HIV disease progression by hormonal contraceptive method: secondary analysis of a randomized trial
  136. Implementation of ‘see-and-treat’ cervical cancer prevention services linked to HIV care in Zambia
  137. Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia
  138. Use of task-shifting to rapidly scale-up HIV treatment services: experiences from Lusaka, Zambia
  139. A Pilot Study of Food Supplementation to Improve Adherence to Antiretroviral Therapy Among Food-Insecure Adults in Lusaka, Zambia
  140. Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia
  141. Declining HIV prevalence among young pregnant women in Lusaka, Zambia
  142. Management of cryotherapy-ineligible women in a “screen-and-treat” cervical cancer prevention program targeting HIV-infected women in Zambia: Lessons from the field
  143. Integrating cervical cancer prevention in HIV/AIDS treatment and care programmes
  144. Simple Adherence Assessments to Predict Virologic Failure among HIV-Infected Adults with Discordant Immunologic and Clinical Responses to Antiretroviral Therapy
  145. Extended nevirapine prophylaxis to prevent HIV transmission
  146. Manual Trephination of Mushroom Keratoplasty in Advanced Keratoconus
  147. Addition of Single-Dose Tenofovir and Emtricitabine to Intrapartum Nevirapine to Reduce Perinatal HIV Transmission
  148. Community-based follow-up for late patients enrolled in a district-wide programme for antiretroviral therapy in Lusaka, Zambia
  149. Monitoring effectiveness of programmes to prevent mother-to-child HIV transmission in lower-income countries
  150. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial
  151. Two Decades of the Safe Motherhood Initiative
  152. Clinical Outcomes and CD4 Cell Response in Children Receiving Antiretroviral Therapy at Primary Health Care Facilities in Zambia
  153. Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter?
  154. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus
  155. Influence of body mass index on pregnancy outcomes among HIV-infected and HIV-uninfected Zambian women
  156. Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine
  157. Expanded Services for the Prevention of Mother-to-Child HIV Transmission
  158. Prevalence and distribution of HPV genotypes among HIV-infected women in Zambia
  159. Complete Blood Cell Count as a Surrogate CD4 Cell Marker for HIV Monitoring in Resource-Limited Settings
  160. Use of Traditional Medicine among Pregnant Women in Lusaka, Zambia
  161. Field Performance of a Thin-Layer Chromatography Assay for Detection of Nevirapine in Umbilical Cord Blood
  162. Rapid Scale-up of Antiretroviral Therapy at Primary Care Sites in Zambia
  163. Individual-Level Predictors for HIV Testing Among Antenatal Attendees in Lusaka, Zambia
  164. HIVCORPS: USING VOLUNTEERS TO RAPIDLY EXPAND HIV HEALTH SERVICES ACROSS ZAMBIA
  165. Subclinical Chorioamnionitis As a Targetable Risk Factor for Vertical Transmission of HIV-1
  166. Acute and chronic chorioamnionitis and the risk of perinatal human immunodeficiency virus-1 transmission
  167. Cost and Enrollment Implications of Targeting Different Source Population for an HIV Treatment Program
  168. Employment of Off-Duty Staff: A Strategy to Meet the Human Resource Needs for a Large PMTCT Program in Zambia
  169. Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia
  170. Potential Cost-Effectiveness of Maternal and Infant Antiretroviral Interventions to Prevent Mother-to-Child Transmission During Breast-feeding
  171. Perceptions toward HIV, HIV Screening, and the Use of Antiretroviral Medications: A Survey of Maternity-Based Health Care Providers in Zambia
  172. Prevention of pediatrichuman immunodeficiency virus
  173. Rapid testing strategies for HIV-1 serodiagnosis in high-prevalence African settings
  174. Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings
  175. An outcomes analysis of five prenatal screening strategies for trisomy 21 in women younger than 35 years
  176. Detection of Nevirapine in Plasma Using Thin-Layer Chromatography
  177. Effects of Concentration and Temperature on the Stability of Nevirapine in Whole Blood and Serum
  178. Personal Risk Perception, HIV Knowledge and Risk Avoidance Behavior, and Their Relationships to Actual HIV Serostatus in an Urban African Obstetric Population
  179. Nevirapine to prevent mother-to-child transmission of HIV-1 among women of unknown serostatus
  180. Monitoring nevirapine-based programmes for prevention of mother-to-child transmission of HIV-1
  181. Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine
  182. Mother-to-child HIV transmission prevention in Thailand: physician zidovudine use and willingness to provide care
  183. Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia
  184. Cesarean Delivery and Risk of Herpes Simplex Virus Infection—Reply
  185. A cost-effectiveness analysis of management strategies for cervical intraepithelial neoplasia grades 2 and 3
  186. Comparison of Two Strategies for Administering Nevirapine to Prevent Perinatal HIV Transmission in High-Prevalence, Resource-Poor Settings
  187. Effect of Nevirapine Toxicity on Choice of Perinatal HIV Prevention Strategies
  188. Perinatal HIV transmission: developing country considerations
  189. Evaluation of a new testing policy for human immunodeficiency virus to improve screening rates
  190. Zambian women's attitudes toward mass nevirapine therapy to prevent perinatal transmission of HIV
  191. Selected Topics from the 13th International AIDS Conference, July 9–14, 2000 Durban, South Africa
  192. An appraisal of screening for maternal type-specific herpes simplex virus antibodies to prevent neonatal herpes
  193. Cost-Effective Use of Nevirapine to Prevent Vertical HIV Transmission in Sub-Saharan Africa
  194. Prevention of mother-to-child transmission of HIV-1
  195. Prevention of Mother-to-Child Transmission of HIV in Thailand: Physicians' Attitudes on Zidovudine Use, Pregnancy Termination, and Willingness to Provide Care.
  196. Rapid testing and zidovudine treatment to prevent vertical transmission of human immunodeficiency virus in unregistered parturients: a cost-effectiveness analysis
  197. Prophylactic Cesarean Delivery for the Prevention of Perinatal Human Immunodeficiency Virus Transmission